Knockdown of mTOR by lentivirus‑mediated RNA interference suppresses atherosclerosis and stabilizes plaques via a decrease of macrophages by autophagy in apolipoprotein E‑deficient mice

Wang,Xiaochuang; Li,Lingxia; Li,Manxiang; Dang,Xiaoyan; Wan,Lin; Wang,Ni; Bi,Xiaoju; Gu,Changwei; Qiu,Suijuan; Niu,Xiaolin; Zhu,Xinye; Wang,Lina

doi:10.3892/ijmm.2013.1494

Knockdown of mTOR by lentivirus‑mediated RNA interference suppresses atherosclerosis and stabilizes plaques via a decrease of macrophages by autophagy in apolipoprotein E‑deficient mice

Authors:
- Xiaochuang Wang
- Lingxia Li
- Manxiang Li
- Xiaoyan Dang
- Lin Wan
- Ni Wang
- Xiaoju Bi
- Changwei Gu
- Suijuan Qiu
- Xiaolin Niu
- Xinye Zhu
- Lina Wang
View Affiliations

Affiliations: Department of Emergency Medicine, the Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, The Cadre Ward, the Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Respiratory Diseases, the Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Cardiovascular Medicine, the Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China
Published online on: September 12, 2013 https://doi.org/10.3892/ijmm.2013.1494
Pages: 1215-1221

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atherosclerotic plaque destabilization and rupture leads to acute coronary syndromes which cause serious damage to human health worldwide. However, there is currently a lack of efficient therapeutic methods. Mammalian target of rapamycin (mTOR) has been suggested to be involved in the development of atherosclerotic plaques and serves as a therapeutic target. The present study was performed to determine whether RNA interference (RNAi) of mTOR in vivo by LV‑mediated small hairpin RNA (shRNA) was capable of inhibiting the progression of atherosclerotic plaques. LV‑mediated shRNA against mTOR (LV‑shmTOR) was designed and obtained. Male apolipoprotein E‑deficient mice were fed a high‑fat diet and a constrictive collar was placed around the right carotid arteries of these mice to induce plaque formation. Eight weeks after surgery, mice were randomly divided into the mTOR RNA interference (LV‑shmTOR) group, receiving treatment with LV‑mTOR‑shRNA; the LV‑shCON group, receiving treatment with LV‑non‑specific‑shRNA; and the control group, receiving treatment with phosphate‑buffered saline. Following transfection, the mice were sacrificed to evaluate the effects of mTOR expression silencing on atherosclerosis. Transfection of LV‑mTOR‑shRNA markedly inhibited the mRNA and protein expression levels. Knockdown of mTOR ameliorated dysregulated blood lipid metabolism and stabilized aortic atherosclerotic plaques by decreasing the plaque area and increasing the fibrous cap and cap‑to‑core ratio. Furthermore, macrophages were decreased by silencing mTOR in atherosclerotic plaques. In addition, western blot analysis revealed that the knockdown of mTOR increased autophagy‑related protein 13 (Atg13) dephosphorylation and light chain 3‑I/light chain 3‑II (LC3‑I/LC3‑II) ratios, both of which were associated with a high activity of autophagy, suggesting an increase of autophagy in atherosclerotic plaques. Moreover, genes including matrix metalloproteinase 2, monocyte chemoattractant protein 1 and tissue factor, which promote plaque instability, were downregulated by silencing mTOR. These results demonstrate that LV‑mediated mTOR silencing by RNAi treatment induces macrophage autophagy and is a potential strategy for the treatment of atherosclerotic plaques.

View Figures

View References

1	Davies MJ and Thomas AC: Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 53:363–373. 1985. View Article : Google Scholar : PubMed/NCBI
2	Falk E, Shah PK and Fuster V: Coronary plaque disruption. Circulation. 92:657–671. 1995. View Article : Google Scholar : PubMed/NCBI
3	Davies MJ, Richardson PD, Woolf N, Katz DR and Mann J: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 69:377–381. 1993. View Article : Google Scholar : PubMed/NCBI
4	Virmani R, Burke AP, Farb A and Kolodgie FD: Pathology of the vulnerable plaque. J Am Coll Cardiol. 47:C13–C18. 2006. View Article : Google Scholar : PubMed/NCBI
5	Mizuno Y, Jacob RF and Mason R: Inflammation and the development of atherosclerosis. J Atheroscler Thromb. 18:351–358. 2011. View Article : Google Scholar : PubMed/NCBI
6	Libby P, Ridker PM and Maseri A: Inflammation and atherosclerosis. Circulation. 105:1135–1143. 2002. View Article : Google Scholar : PubMed/NCBI
7	Shah PK, Falk E, Badimon JJ, et al: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 92:1565–1569. 1995.
8	Niu J and Kolattukudy PE: Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond). 117:95–109. 2009. View Article : Google Scholar : PubMed/NCBI
9	Lwaleed BA, Cooper AJ, Voegeli D and Getliffe K: Tissue factor: a critical role in inflammation and cancer. Biol Res Nurs. 9:97–107. 2007. View Article : Google Scholar : PubMed/NCBI
10	Boyle JJ: Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol. 3:63–68. 2005. View Article : Google Scholar : PubMed/NCBI
11	Verheye S, Martinet W, Kockx MM, et al: Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol. 49:706–715. 2007. View Article : Google Scholar : PubMed/NCBI
12	Thomas G and Hall MN: TOR signalling and control of cell growth. Curr Opin Cell Biol. 9:782–787. 1997. View Article : Google Scholar : PubMed/NCBI
13	Dennis PB, Fumagalli S and Thomas G: Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev. 9:49–54. 1999. View Article : Google Scholar : PubMed/NCBI
14	Easton JB and Houghton PJ: Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets. 8:551–564. 2004. View Article : Google Scholar : PubMed/NCBI
15	Woltman AM, van der Kooij SW, Coffer PJ, et al: Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood. 101:1439–1445. 2003. View Article : Google Scholar : PubMed/NCBI
16	Huang S, Shu L, Dilling MB, et al: Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell. 11:1491–1501. 2003. View Article : Google Scholar : PubMed/NCBI
17	Ravikumar B, Vacher C, Berger Z, et al: Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 36:585–595. 2004. View Article : Google Scholar
18	Noda T and Ohsumi Y: Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem. 273:3963–3966. 1998. View Article : Google Scholar : PubMed/NCBI
19	Abraham RT and Gibbons JJ: The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res. 13:3109–3114. 2007. View Article : Google Scholar : PubMed/NCBI
20	Suzuki T, Kopia G, Hayashi S, et al: Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 104:1188–1193. 2001. View Article : Google Scholar : PubMed/NCBI
21	Elloso MM, Azrolan N, Sehgal SN, et al: Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant. 3:562–569. 2003. View Article : Google Scholar : PubMed/NCBI
22	Mizushima N and Komatsu M: Autophagy: renovation of cells and tissues. Cell. 147:728–741. 2011. View Article : Google Scholar : PubMed/NCBI
23	Yang Z and Klionsky DJ: Eaten alive: a history of macroautophagy. Nat Cell Biol. 12:814–822. 2010. View Article : Google Scholar : PubMed/NCBI
24	Chen Y, Lin MC, Yao H, et al: Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology. 46:200–208. 2007. View Article : Google Scholar
25	Jiang L, Lai YK, Zhang J, et al: Targeting S100P inhibits colon cancer growth and metastasis by lentivirus-mediated RNA interference and proteomic analysis. Mol Med. 17:709–716. 2011. View Article : Google Scholar : PubMed/NCBI
26	von der Thusen JH, van Berkel TJ and Biessen EA: Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation. 103:1164–1170. 2001.PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2−(Delta Delta C(T)) method. Methods. 25:402–408. 2001.
28	Levine B and Klionsky DJ: Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 6:463–477. 2004. View Article : Google Scholar : PubMed/NCBI
29	Mizushima N: Methods for monitoring autophagy. Int J Biochem Cell Biol. 36:2491–2502. 2004. View Article : Google Scholar
30	Toth PP: High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol. 96:50K–58K. 2005. View Article : Google Scholar : PubMed/NCBI
31	Ma KL, Ruan XZ, Powis SH, Moorhead JF and Varghese Z: Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 292:H2721–H2728. 2007. View Article : Google Scholar : PubMed/NCBI
32	Ma KL, Varghese Z, Ku Y, et al: Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 298:H1646–H1651. 2010. View Article : Google Scholar
33	Mathis AS, Jin S, Friedman GS, et al: The pharmacodynamic effects of sirolimus and sirolimus-calcineurin inhibitor combinations on macrophage scavenger and nuclear hormone receptors. J Pharm Sci. 96:209–222. 2007. View Article : Google Scholar
34	Croons V, Martinet W, Herman AG, Timmermans JP and De Meyer GR: Selective clearance of macrophages in atherosclerotic plaques by the protein synthesis inhibitor cycloheximide. J Pharmacol Exp Ther. 320:986–993. 2007. View Article : Google Scholar : PubMed/NCBI
35	Martinet W, Verheye S, De Meyer I, et al: Everolimus triggers cytokine release by macrophages: rationale for stents eluting everolimus and a glucocorticoid. Arterioscler Thromb Vasc Biol. 32:1228–1235. 2012. View Article : Google Scholar : PubMed/NCBI
36	Huang WP, Scott SV, Kim J and Klionsky DJ: The itinerary of a vesicle component, Aut7p/Cvt5p, terminates in the yeast vacuole via the autophagy/Cvt pathways. J Biol Chem. 275:5845–5851. 2000. View Article : Google Scholar : PubMed/NCBI
37	Chan TF, Bertram PG, Ai W and Zheng XF: Regulation of APG14 expression by the GATA-type transcription factor Gln3p. J Biol Chem. 276:6463–6467. 2001. View Article : Google Scholar : PubMed/NCBI
38	Crouzet J, Faucher JF, Toubin M, Hoen B and Estavoyer JM: Serum C-reactive protein (CRP) and procalcitonin (PCT) levels and kinetics in patients with leptospirosis. Eur J Clin Microbiol Infect Dis. 30:299–302. 2011. View Article : Google Scholar : PubMed/NCBI
39	Bea F, Blessing E, Bennett B, et al: Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol. 22:1832–1837. 2002. View Article : Google Scholar : PubMed/NCBI
40	Zaman AG, Helft G, Worthley SG and Badimon JJ: The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis. 149:251–266. 2000. View Article : Google Scholar : PubMed/NCBI
41	Morancho A, Rosell A, García-Bonilla L and Montaner J: Metalloproteinase and stroke infarct size: role for anti-inflammatory treatment? Ann NY Acad Sci. 1207:123–133. 2010. View Article : Google Scholar : PubMed/NCBI
42	Deshmane SL, Kremlev S, Amini S and Sawaya BE: Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 29:313–326. 2009. View Article : Google Scholar : PubMed/NCBI
43	Rull A, Beltrán-Debón R, Aragonès G, et al: Expression of cytokine genes in the aorta is altered by the deficiency in MCP-1: effect of a high-fat, high-cholesterol diet. Cytokine. 50:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
44	Liu XL, Zhang PF, Ding SF, et al: Local gene silencing of monocyte chemoattractant protein-1 prevents vulnerable plaque disruption in apolipoprotein E-knockout mice. PLoS One. 7:e334972012. View Article : Google Scholar : PubMed/NCBI
45	Jude B, Zawadzki C, Susen S and Corseaux D: Relevance of tissue factor in cardiovascular disease. Arch Mal Coeur Vaiss. 98:667–671. 2005.PubMed/NCBI
46	Kume N: Molecular mechanisms of coronary atherosclerotic plaque formation and rupture. Nihon Rinsho. 68:637–641. 2010.(In Japanese).
47	Song E, Lee SK, Wang J, et al: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 9:347–351. 2003. View Article : Google Scholar : PubMed/NCBI
48	Paroo Z and Corey DR: Challenges for RNAi in vivo. Trends Biotechnol. 22:390–394. 2004. View Article : Google Scholar : PubMed/NCBI